ADC Therapeutics (ADCT) Stock Forecast & Price Target

ADC Therapeutics is supported by ZYNLONTA’s commercial approval, which materially lowers regulatory risk while already generating tangible cash flows and giving the company a marketed asset in relapsed or refractory large B-cell lymphoma. Its efficacy strengthens physician adoption and supports the potential for broader use across indications, including upside in additional indolent lymphomas, while the pipeline adds optionality through LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241. The capital raise in 4Q25 extends cash runway until 2028, giving the company sufficient financial flexibility to pursue expansion into earlier lines of treatment and capture additional growth.

ADC Therapeutics is facing a deteriorating fundamental outlook because ZYNLONTA’s confirmatory LOTIS-5 trial, despite meeting PFS (HR 0.73), failed to improve OS (HR 0.96) and showed an elevated rate of Grade 5 adverse events, prompting the FDA to flag “substantial concerns” about benefit-risk and verification of clinical benefit. Commercially, 2Q net sales of $18.6M were only stable rather than accelerating, while the company remains dependent on a single marketed asset in a crowded DLBCL landscape with limited differentiation versus other therapies. Although it ended the quarter with $219M in cash and guided runway “at least into 2028,” the need for restructuring, lower risk-adjusted revenue assumptions, and reduced approval probability to 50% underscore rising regulatory and execution risk.